Review



ps6 s240 244  (Cell Signaling Technology Inc)


Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 97
      Buy from Supplier

    Structured Review

    Cell Signaling Technology Inc ps6 s240 244
    Ps6 S240 244, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 97/100, based on 2108 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ps6 s240 244/product/Cell Signaling Technology Inc
    Average 97 stars, based on 2108 article reviews
    ps6 s240 244 - by Bioz Stars, 2026-03
    97/100 stars

    Images



    Similar Products

    ps6 s240 244  (Cell Signaling Technology Inc)
    97
    Cell Signaling Technology Inc ps6 s240 244
    Ps6 S240 244, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ps6 s240 244/product/Cell Signaling Technology Inc
    Average 97 stars, based on 1 article reviews
    ps6 s240 244 - by Bioz Stars, 2026-03
    97/100 stars
    		  Buy from Supplier
    ps6 s240  (Cell Signaling Technology Inc)
    97
    Cell Signaling Technology Inc ps6 s240
    ( A – D ) OGT, <t>pS6</t> <t>S240,</t> S6, and O-GlcNAcylation (RL2 antibody) levels from WT mouse islets from the offspring born to dam fed control diet (CtrlD) or low protein diet during pregnancy (LPD) ( n = 4–7). ( E ) β Cell area to pancreas area ratio from control and eIF4EBP2-KO (BP2-KO) neonatal mice born to either dam fed CtrlD or low protein diet ( n = 8–11). ( F – I ) Representative immunoblot and analysis of pS6 S240, S6, RL2 (pan-O-GlcNAc), and LC3 from islets from patients who are lean or have obesity ( n = 4–5). ( J – O ) Islets from patients who are lean or have obesity were treated with low or high glucose (L, 3 mM; H, 16.7 mM), amino acid (A), and/or palmitate/BSA (P; 16:4; 100 μM; palmitate [Palm]) for 6 hours and assessed in immunoblot for pS6 S240, S6 and RL2 (pan-O-GlcNAc) ( n = 3–4 donors). One of 4 obese donor islets did not show any RL2 signaling. Statistical analysis by Student’s t test ( B – E , and G – I ) and 1-way ANOVA ( K , L , N , and O ). * P ≤ 0.05, *** P < 0.001.
    Ps6 S240, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ps6 s240/product/Cell Signaling Technology Inc
    Average 97 stars, based on 1 article reviews
    ps6 s240 - by Bioz Stars, 2026-03
    97/100 stars
    		  Buy from Supplier
    anti-ps6 s240/s244  (Cell Signaling Technology Inc)
    90
    Cell Signaling Technology Inc anti-ps6 s240/s244
    ( A – D ) OGT, <t>pS6</t> <t>S240,</t> S6, and O-GlcNAcylation (RL2 antibody) levels from WT mouse islets from the offspring born to dam fed control diet (CtrlD) or low protein diet during pregnancy (LPD) ( n = 4–7). ( E ) β Cell area to pancreas area ratio from control and eIF4EBP2-KO (BP2-KO) neonatal mice born to either dam fed CtrlD or low protein diet ( n = 8–11). ( F – I ) Representative immunoblot and analysis of pS6 S240, S6, RL2 (pan-O-GlcNAc), and LC3 from islets from patients who are lean or have obesity ( n = 4–5). ( J – O ) Islets from patients who are lean or have obesity were treated with low or high glucose (L, 3 mM; H, 16.7 mM), amino acid (A), and/or palmitate/BSA (P; 16:4; 100 μM; palmitate [Palm]) for 6 hours and assessed in immunoblot for pS6 S240, S6 and RL2 (pan-O-GlcNAc) ( n = 3–4 donors). One of 4 obese donor islets did not show any RL2 signaling. Statistical analysis by Student’s t test ( B – E , and G – I ) and 1-way ANOVA ( K , L , N , and O ). * P ≤ 0.05, *** P < 0.001.
    Anti Ps6 S240/S244, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti-ps6 s240/s244/product/Cell Signaling Technology Inc
    Average 90 stars, based on 1 article reviews
    anti-ps6 s240/s244 - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    anti-ps6 (s240/s244) #k006232p  (Beijing Solarbio Science)
    90
    Beijing Solarbio Science anti-ps6 (s240/s244) #k006232p
    ( A – D ) OGT, <t>pS6</t> <t>S240,</t> S6, and O-GlcNAcylation (RL2 antibody) levels from WT mouse islets from the offspring born to dam fed control diet (CtrlD) or low protein diet during pregnancy (LPD) ( n = 4–7). ( E ) β Cell area to pancreas area ratio from control and eIF4EBP2-KO (BP2-KO) neonatal mice born to either dam fed CtrlD or low protein diet ( n = 8–11). ( F – I ) Representative immunoblot and analysis of pS6 S240, S6, RL2 (pan-O-GlcNAc), and LC3 from islets from patients who are lean or have obesity ( n = 4–5). ( J – O ) Islets from patients who are lean or have obesity were treated with low or high glucose (L, 3 mM; H, 16.7 mM), amino acid (A), and/or palmitate/BSA (P; 16:4; 100 μM; palmitate [Palm]) for 6 hours and assessed in immunoblot for pS6 S240, S6 and RL2 (pan-O-GlcNAc) ( n = 3–4 donors). One of 4 obese donor islets did not show any RL2 signaling. Statistical analysis by Student’s t test ( B – E , and G – I ) and 1-way ANOVA ( K , L , N , and O ). * P ≤ 0.05, *** P < 0.001.
    Anti Ps6 (S240/S244) #K006232p, supplied by Beijing Solarbio Science, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti-ps6 (s240/s244) #k006232p/product/Beijing Solarbio Science
    Average 90 stars, based on 1 article reviews
    anti-ps6 (s240/s244) #k006232p - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    ( A – D ) OGT, pS6 S240, S6, and O-GlcNAcylation (RL2 antibody) levels from WT mouse islets from the offspring born to dam fed control diet (CtrlD) or low protein diet during pregnancy (LPD) ( n = 4–7). ( E ) β Cell area to pancreas area ratio from control and eIF4EBP2-KO (BP2-KO) neonatal mice born to either dam fed CtrlD or low protein diet ( n = 8–11). ( F – I ) Representative immunoblot and analysis of pS6 S240, S6, RL2 (pan-O-GlcNAc), and LC3 from islets from patients who are lean or have obesity ( n = 4–5). ( J – O ) Islets from patients who are lean or have obesity were treated with low or high glucose (L, 3 mM; H, 16.7 mM), amino acid (A), and/or palmitate/BSA (P; 16:4; 100 μM; palmitate [Palm]) for 6 hours and assessed in immunoblot for pS6 S240, S6 and RL2 (pan-O-GlcNAc) ( n = 3–4 donors). One of 4 obese donor islets did not show any RL2 signaling. Statistical analysis by Student’s t test ( B – E , and G – I ) and 1-way ANOVA ( K , L , N , and O ). * P ≤ 0.05, *** P < 0.001.

    Journal: JCI Insight

    Article Title: Loss of O-GlcNAcylation modulates mTORC1 and autophagy in β cells, driving diabetes 2 progression

    doi: 10.1172/jci.insight.183033

    Figure Lengend Snippet: ( A – D ) OGT, pS6 S240, S6, and O-GlcNAcylation (RL2 antibody) levels from WT mouse islets from the offspring born to dam fed control diet (CtrlD) or low protein diet during pregnancy (LPD) ( n = 4–7). ( E ) β Cell area to pancreas area ratio from control and eIF4EBP2-KO (BP2-KO) neonatal mice born to either dam fed CtrlD or low protein diet ( n = 8–11). ( F – I ) Representative immunoblot and analysis of pS6 S240, S6, RL2 (pan-O-GlcNAc), and LC3 from islets from patients who are lean or have obesity ( n = 4–5). ( J – O ) Islets from patients who are lean or have obesity were treated with low or high glucose (L, 3 mM; H, 16.7 mM), amino acid (A), and/or palmitate/BSA (P; 16:4; 100 μM; palmitate [Palm]) for 6 hours and assessed in immunoblot for pS6 S240, S6 and RL2 (pan-O-GlcNAc) ( n = 3–4 donors). One of 4 obese donor islets did not show any RL2 signaling. Statistical analysis by Student’s t test ( B – E , and G – I ) and 1-way ANOVA ( K , L , N , and O ). * P ≤ 0.05, *** P < 0.001.

    Article Snippet: Primary antibodies (TSC2 [4308; Cell Signaling Technology], pS6 S240 [5364; Cell Signaling Technology], S6 [sc-74459; Santa Cruz Biotechnology Inc.], RL2 [ab2739; Abcam], OGT [24083; Cell Signaling Technology], OGA [SAB4200267; MilliporeSigma], mTOR [2983; Cell Signaling Technology], Actin [4967; Cell Signaling Technology], Vinculin [E1E9V; Cell Signaling Technology], Tubulin [2146; Cell Signaling Technology], LC3B [3868; Cell Signaling Technology], p62 [5114; Cell Signaling Technology]) were applied, followed by horseradish peroxidase–conjugated secondary antibodies.

    Techniques: Control, Western Blot

    ( A ) qPCR analysis of Tsc2 mRNA from male and female, control and βOGT-KO islets; normalized to 36B4 ( n = 3-4). ( B – D ) Representative immunoblot and analysis of TSC2, pS6 S240, and S6 from control and βOGT-KO islets ( n = 3-4). ( E ) Quantatitative PCR analysis of Tsc2 mRNA from male control and βOGA-KO islets; normalized to 36B4 ( n = 4). ( F – H ) Representative immunoblot and analysis of TSC2 and pS6 S240 from control and βOGA-KO islets ( n = 3–5). ( I ) Representative immunofluorescence imaging and quantification of insulin, pS6 S240, and RL2 from histogel embedded human donor (lean) islets treated with vehicle/control or TMG (30 μM) for 12 hours. Magnification, ×600. Scale bar: 100 μm. Statistical analysis by Student’s t test. * P ≤ 0.05, ** P < 0.01, *** P < 0.001.

    Journal: JCI Insight

    Article Title: Loss of O-GlcNAcylation modulates mTORC1 and autophagy in β cells, driving diabetes 2 progression

    doi: 10.1172/jci.insight.183033

    Figure Lengend Snippet: ( A ) qPCR analysis of Tsc2 mRNA from male and female, control and βOGT-KO islets; normalized to 36B4 ( n = 3-4). ( B – D ) Representative immunoblot and analysis of TSC2, pS6 S240, and S6 from control and βOGT-KO islets ( n = 3-4). ( E ) Quantatitative PCR analysis of Tsc2 mRNA from male control and βOGA-KO islets; normalized to 36B4 ( n = 4). ( F – H ) Representative immunoblot and analysis of TSC2 and pS6 S240 from control and βOGA-KO islets ( n = 3–5). ( I ) Representative immunofluorescence imaging and quantification of insulin, pS6 S240, and RL2 from histogel embedded human donor (lean) islets treated with vehicle/control or TMG (30 μM) for 12 hours. Magnification, ×600. Scale bar: 100 μm. Statistical analysis by Student’s t test. * P ≤ 0.05, ** P < 0.01, *** P < 0.001.

    Article Snippet: Primary antibodies (TSC2 [4308; Cell Signaling Technology], pS6 S240 [5364; Cell Signaling Technology], S6 [sc-74459; Santa Cruz Biotechnology Inc.], RL2 [ab2739; Abcam], OGT [24083; Cell Signaling Technology], OGA [SAB4200267; MilliporeSigma], mTOR [2983; Cell Signaling Technology], Actin [4967; Cell Signaling Technology], Vinculin [E1E9V; Cell Signaling Technology], Tubulin [2146; Cell Signaling Technology], LC3B [3868; Cell Signaling Technology], p62 [5114; Cell Signaling Technology]) were applied, followed by horseradish peroxidase–conjugated secondary antibodies.

    Techniques: Control, Western Blot, Immunofluorescence, Imaging

    ( A – C ) Representative immunoblot and analysis of TSC2, pS6 S240, and S6 from control, βOGT-KO, βOGT/TSC2-KO, and βTSC2-KO islets ( n = 4–5). ( D – H ) Nonfasted blood glucose over time, i.p. glucose tolerance (glucose 2 g/kg i.p.), and insulin tolerance test (insulin 0.75U/kg i.p.) from male and female control, βOGT-KO, βOGT/TSC2-KO, and βTSC2-KO mice ( n = 3–8). ( I ) In vivo GSIS assay from male control, βOGT-KO, and βOGT/TSC2-KO mice ( n = 4–7). * P ≤ 0.05, Ctrl versus βOGT-KO or βOGT/TSC2-KO, ** P < 0.01, *** P < 0.001, **** P < 0.0001. Statistical analysis by 1-way ( B and C , AUC for E – H ) and 2-way ANOVA ( D and I ).

    Journal: JCI Insight

    Article Title: Loss of O-GlcNAcylation modulates mTORC1 and autophagy in β cells, driving diabetes 2 progression

    doi: 10.1172/jci.insight.183033

    Figure Lengend Snippet: ( A – C ) Representative immunoblot and analysis of TSC2, pS6 S240, and S6 from control, βOGT-KO, βOGT/TSC2-KO, and βTSC2-KO islets ( n = 4–5). ( D – H ) Nonfasted blood glucose over time, i.p. glucose tolerance (glucose 2 g/kg i.p.), and insulin tolerance test (insulin 0.75U/kg i.p.) from male and female control, βOGT-KO, βOGT/TSC2-KO, and βTSC2-KO mice ( n = 3–8). ( I ) In vivo GSIS assay from male control, βOGT-KO, and βOGT/TSC2-KO mice ( n = 4–7). * P ≤ 0.05, Ctrl versus βOGT-KO or βOGT/TSC2-KO, ** P < 0.01, *** P < 0.001, **** P < 0.0001. Statistical analysis by 1-way ( B and C , AUC for E – H ) and 2-way ANOVA ( D and I ).

    Article Snippet: Primary antibodies (TSC2 [4308; Cell Signaling Technology], pS6 S240 [5364; Cell Signaling Technology], S6 [sc-74459; Santa Cruz Biotechnology Inc.], RL2 [ab2739; Abcam], OGT [24083; Cell Signaling Technology], OGA [SAB4200267; MilliporeSigma], mTOR [2983; Cell Signaling Technology], Actin [4967; Cell Signaling Technology], Vinculin [E1E9V; Cell Signaling Technology], Tubulin [2146; Cell Signaling Technology], LC3B [3868; Cell Signaling Technology], p62 [5114; Cell Signaling Technology]) were applied, followed by horseradish peroxidase–conjugated secondary antibodies.

    Techniques: Western Blot, Control, In Vivo